A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study, according to a recent presentation.
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study, according to a recent presentation.